8Suppliers
2Customers
2Debt Items
20Related Chains

Zura Bio Limited Suppliers

TickerNameConfidenceEvidence
ATHANOR ATHANOR 90% the Company agreed to pay an amount equal to 2% of Net Sales (as defined in the Athanor Agreement) for the Product (as defined in the Athanor Agreement) to the extent such Net Sales (collectively, th…
PFE Pfizer Inc. 90% We are party to a license agreement with Pfizer under which we were granted rights to certain patents, know-how and technology that are important and necessary to our business, including for crebankitug.
PFE Pfizer Inc. 90% Reciprocal relationship from PFE graph: Reciprocal relationship from ZURA graph: We are party to a license agreement with Pfizer under which we were granted rights to certain patents, know-how and te…
WUXI-BIOLOGICS WUXI-BIOLOGICS 90% If the Company manufactures all of its commercial supplies of bulk drug product for WuXi Biologics Licensed Products with a manufacturer other than WuXi Biologics or its affiliates, the Company is re…
BAFFX17 BAFFX17 80% the Company and its subsidiaries, on the one hand, and Stone Peach or BAFFX17, on the other hand, including the extinguishment of any and all rights or claims Stone Peach or BAFFX17 may have under al…
STONE-PEACH STONE-PEACH 80% the Company and its subsidiaries, on the one hand, and Stone Peach or BAFFX17, on the other hand, including the extinguishment of any and all rights or claims Stone Peach or BAFFX17 may have under al…
SNYNF Sanofi 72% nst such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could ad…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZURA graph: nst such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our pr…

Zura Bio Limited Customers

TickerNameConfidenceEvidence
SNYNF Sanofi 72% nst such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could ad…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZURA graph: nst such party. Costly and time-c…

Zura Bio Limited Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZURA-DEBT-13792 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.
ZURA-DEBT-13791 Warrants outstanding: 0.001 90% xbrl warrant detail from xbrl 2025-09-30.

Zura Bio Limited Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zura Bio Limited.

Zura Bio Limited Ownership

HolderNameConfidenceEvidence
ZURA-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC SUVRETTA CAPITAL MANAGEMENT, LLC 90% 13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 95 tracked holders.

Zura Bio Limited Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ACIU AC Immune SA 100.00 2
VEEV Veeva Systems Inc. 100.00 2
BYSI BeyondSpring Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
ACRS Aclaris Therapeutics, Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
VNDA Vanda Pharmaceuticals Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 2
IMNM Immunome, Inc. 100.00 2